Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

被引：0
|
作者：
Dhawan, Ravinder [1 ]
Robinson, Don, Jr. [1 ]
Meunier, Juliette [2 ]
Regnault, Antoine [2 ]
Rosa, Kathleen [3 ]
Cakana, Andrew Z. [4 ]
van de Velde, Helgi [5 ]
Richardson, Paul G. [6 ]
San Miguel, Jesus F. [7 ]
机构：
[1] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA
[2] Mapi Values, Lyon, France
[3] Mapi Values, Boston, MA USA
[4] Johnson & Johnson Pharmaceut Res & Dev, High Wycombe, Bucks, England
[5] Johnson & Johnson Pharmaceut Res & Dev, Bonaire, Neth Antilles
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Hosp Univ Salamanca, Hematol Serv, Salamanca, Spain
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：747 / 747
页数：1
相关论文
共 50 条
  • [21] Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Lewis, Philip
    Millar, Stefanie
    Zhang, Jingshan
    Mei, Jay
    Delforge, Michel
    LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1489 - 1497
  • [22] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
    Fu, Weijun
    Bang, Soo-Mee
    Huang, Honghui
    Kim, Kihyun
    Li, Wei
    An, Gang
    Lee, Je-Jung
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, Chor Sang
    Carson, Robin
    Liu, Rui
    Zhao, Man
    Chen, Xi
    Cui, Canchan
    Hou, Jian
    Wang, Jianxiang
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525
  • [23] Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Multiple Myeloma
    Ricci, Deborah S.
    Favis, Reyna
    Sun, Yu
    van de Velde, Helgi
    Broderick, Erin
    Meyers, Michael
    Harousseau, Jean-Luc
    Avet-Loiseau, Herve
    Richardson, Paul G.
    San Miguel, Jesus F.
    BLOOD, 2009, 114 (22) : 1491 - 1491
  • [24] BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS MP AS INITIAL TREATMENT FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Kim, M. K.
    Kim, K.
    Yoon, D. H.
    Suh, C.
    Moon, J. H.
    Lee, Y. J.
    Lee, J. H.
    Jung, S. -H.
    Kim, H. J.
    Bae, S. H.
    Kim, J. S.
    Lee, J. -O.
    Eom, H. S.
    Lee, W. -S.
    Kang, H. J.
    Mun, Y. -C.
    Do, Y. R.
    Hyun, M. S.
    HAEMATOLOGICA, 2017, 102 : 793 - 793
  • [25] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Lee, Jae Hoon
    Moreau, Philippe
    Niesvizky, Ruben
    Dimopoulos, Meletios
    Hajek, Roman
    Pour, Ludek
    Jurczyszyn, Artur
    Qiu, Lugui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Osman, Muhtarjan
    Paiva, Bruno
    San-Miguel, Jesus
    BLOOD, 2019, 133 (18) : 1953 - 1963
  • [26] Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)
    Cavo, Michele
    Dimopoulos, Meletios A.
    San-Miguel, Jesus F.
    Mateos, Maria-Victoria
    Jakubowiak, Andrzej
    Deraedt, William
    Lam, Annette
    Kampfenkel, Tobias
    Qi, Ming
    He, Jianming
    BLOOD, 2018, 132
  • [27] Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Dmide
    Cavalli, Maide
    Ria, Roberto
    Gentilini, Silvia
    Patriarca, Francesca
    Nozzoli, Chiara
    Levi, Anna
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Vincelli, Donatella
    Baldini, Luca
    Morabito, Fortunato
    Grasso, Mariella
    Marasca, Roberto
    Rizzo, Manuela
    Pautasso, Chiara
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musolino, Caterina
    Cangialosi, Clotilde
    Mansueto, Giovanna
    Liberati, Anna Marina
    Magarotto, Valeria
    Omede, Paola
    Musto, Pellegrino
    Petrucci, Maria Teresa
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [28] Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression
    Dimopoulos, Meletios Athanasios
    Delforge, Michel
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Lewis, Philip
    Millar, Stefanie
    Nang, Jingshan
    Mei, Jay
    Palumbo, Antonio
    BLOOD, 2011, 118 (21) : 1365 - 1365
  • [29] Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
    Kim, Min Kyoung
    Kim, Kihyun
    Yoon, Do Hyun
    Suh, Cheolwon
    Moon, Joon Ho
    Lee, Yoo Jin
    Lee, Jae Hoon
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Hyo Jung
    Bae, Sung Hwa
    Kim, Jin Seok
    Lee, Jeong-Ok
    Eom, Hyeon Seok
    Lee, Won-Sik
    Kang, Hye Jin
    Mun, Yeung-Chul
    Do, Young Rok
    Hyun, Myung Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E70 - E70
  • [30] Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gutierrez, Norma
    Teruel, Ana-Isabel
    de Paz, Raquel
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martin, Alejandro
    Diaz Mediavilla, Joaquin
    Palomera, Luis
    de Arriba, Felipe
    Gonzalez, Yolanda
    Hernandez, Jose-Mariano
    Sureda, Ana
    Bello, Jose-Luis
    Bargay, Joan
    Penalver, Francisco-Javier
    Ribera, Jose-Maria
    Martin-Mateos, Maria-Luisa
    Garcia-Sanz, Ramon
    Cibeira, Maria-Teresa
    Martin Ramos, Maria-Luisa
    Vidriales, Maria-Belen
    Paiva, Bruno
    Montalban, Maria-Angeles
    Lahuerta, Juan-Jose
    Blade, Joan
    San Miguel, Jesus-Fernando
    LANCET ONCOLOGY, 2010, 11 (10): : 934 - 941
12345